- Home
- ANIP
as 02-21-2025 4:00pm EST
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Upcoming Earnings Alert:
Get ready for potential market movements as ANI Pharmaceuticals Inc. ANIP prepares to release earnings report on 28 Feb 2025.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | BAUDETTE |
| Market Cap: | 1.2B | IPO Year: | N/A |
| Target Price: | $77.33 | AVG Volume (30 days): | 165.0K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $52.50 - $70.81 | Next Earning Date: | 02-28-2025 |
| Revenue: | $555,456,000 | Revenue Growth: | 23.60% |
| Revenue Growth (this year): | 25.54% | Revenue Growth (next year): | 20.95% |
Stock Insider Trading Activity of ANI Pharmaceuticals Inc. (ANIP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Feb 12 '25 | Sell | $59.54 | 400 | $23,816.00 | 83,478 | |
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Jan 13 '25 | Sell | $53.92 | 400 | $21,568.00 | 83,478 | |
| CAREY STEPHEN P. | ANIP | SVP & CFO | Dec 17 '24 | Sell | $55.79 | 7,500 | $418,425.00 | 154,468 | |
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Dec 13 '24 | Sell | $56.24 | 250 | $14,060.00 | 83,478 | |
| Davis Krista | ANIP | SVP, CHIEF HR OFFICER | Dec 11 '24 | Sell | $60.00 | 1,000 | $60,000.00 | 49,059 | |
| Lalwani Nikhil | ANIP | PRESIDENT & CEO | Nov 26 '24 | Sell | $58.13 | 33,481 | $1,941,442.30 | 373,859 |
Latest ANI Pharmaceuticals Inc. News
ANIP Breaking Stock News: Dive into ANIP Ticker-Specific Updates for Smart Investing
StockStory
a day ago
Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks
GlobeNewswire
3 days ago
ANI Pharmaceuticals to Present at Raymond James’ Institutional Investors and Leerink Partners Global Healthcare Conferences in March
StockStory
3 days ago
Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest
Argus Research
4 days ago
ANIP: Lowering target price to $47.00
GlobeNewswire
4 days ago
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET
Zacks
5 days ago
Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now?
Zacks
5 days ago
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
Zacks
5 days ago
Gilead Sciences, Inc. (GILD) Hit a 52 Week High, Can the Run Continue?
Compare ANIP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANIP ANI Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.